Table 2

Characteristics of patients with recurrences

PatientRecurrence siteHistologyGFIGO stageLSVIAge (years)LN statusAdjuvant treatment
1PelvicSquamousG2IB149+*ChemoRT
2VaginalAdenocarcinomaG1IB139None
3VaginalAdenocarcinomaG1IB153None
4PelvicSquamousG1IB1+51Pre-op brachyth
5LungSquamousIB144None
6Aortic LNSquamousG2IB169ChemoRT*
7VaginalSquamousIB158Pre-op brachyth
8LN+lungSquamousIB152ChemoRT*
9Vaginal+LNSquamousG3IB1†+41ChemoRT
10SacrumSquamousG2IB1+74Pre-op brachyth
11PelvicSquamousG2IB135None
12PelvicSquamousIB156Pre-op brachyth
13PelvicSquamousIB164+**None
  • *Patients refused radical hysterectomy and so were treated with chemoradiotherapy.

  • †Parametrial involvement was demonstrated at the final pathology.

  • ‡SLN positive for macrometastases.

  • §SLN positive for micrometastases.

  • ChemoRT, chemoradiotherapy;FIGO, International Federation of Gynecology and Obstetrics; G, grade;LN, lymph node;LVSI, lymph-vascular space involvement;SLN, sentinel lymph node; pre-op brachyth, pre-operative brachytherapy.